Streetbeat News

Analyst Ratings

CTLT

RBC Capital analyst Sean Dodge has reiterated an Outperform rating on Catalent (NYSE:CTLT) and maintained a $49 price target.

Portfolio Pulse from richadhand@benzinga.com

June 30, 2023 | 12:30 pm

BAC

RBC Capital analyst Gerard Cassidy has reiterated an Outperform rating on Bank of America (NYSE:BAC) and maintained a $35 price target.

Portfolio Pulse from richadhand@benzinga.com

June 30, 2023 | 12:29 pm

TSX:CJR

RBC Capital analyst Drew McReynolds has maintained a 'Sector Perform' rating on Corus Entertainment (TSX:CJR) and lowered the price target from C$3 to C$2.5.

Portfolio Pulse from richadhand@benzinga.com

June 30, 2023 | 12:26 pm

BMRN

The FDA has approved BioMarin Pharmaceutical Inc's Roctavian gene therapy for adults with severe hemophilia A. This is the first approved gene therapy for severe hemophilia A in the U.S. BioMarin will continue to monitor the long-term effects of treatment with an extension study. Analysts from William Blair, Truist Securities, and Wedbush have given positive outlooks for BioMarin, with Truist Securities and Wedbush raising their price targets.

Portfolio Pulse from Vandana Singh

June 30, 2023 | 12:26 pm

TSX:CPX

RBC Capital analyst Maurice Choy has maintained a 'Sector Perform' rating on Capital Power (TSX:CPX), but lowered the price target from C$50 to C$48.

Portfolio Pulse from richadhand@benzinga.com

June 30, 2023 | 12:25 pm

CP

RBC Capital analyst Walter Spracklin maintains an 'Outperform' rating on Canadian Pacific Kansas (TSX:CP) and raises the price target from C$122 to C$125.

Portfolio Pulse from richadhand@benzinga.com

June 30, 2023 | 12:23 pm

PAYX

JP Morgan analyst Tien-Tsin Huang has maintained an 'Underweight' rating on Paychex (NASDAQ:PAYX) and lowered the price target from $123 to $114.

Portfolio Pulse from richadhand@benzinga.com

June 30, 2023 | 12:22 pm

NKE

JP Morgan analyst Matthew Korn maintains an Overweight rating on Nike (NYSE:NKE) but has lowered the price target from $146 to $142.

Portfolio Pulse from richadhand@benzinga.com

June 30, 2023 | 12:21 pm

BTCY

Biotricity (NASDAQ:BTCY) reported Q4 losses of $(0.09) per share, an 18.18% improvement from $(0.11) per share YoY. However, the company's quarterly sales of $2.74 million missed the analyst consensus estimate of $3.16 million by 13.29%, despite a 27.44% increase from $2.15 million YoY.

Portfolio Pulse from Benzinga Newsdesk

June 30, 2023 | 12:21 pm